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AbstrAct
Randomised controlled trials (RCTs) provide the reference 
standard for comparing the efficacy of one therapy or 
intervention with another. However, RCTs have restrictive 
inclusion and exclusion criteria; thus, they are not fully 
representative of an unselected real-world population. 
Real-world evidence (RWE) studies encompass a wide 
range of research methodologies and data sources and 
can be broadly categorised as non-interventional studies, 
patient registries, claims database studies, patient surveys 
and electronic health record studies. If appropriately 
designed, RWE studies include a patient population 
that is far more representative of unselected patient 
populations than those of RCTs, but they do not provide 
a robust basis for comparing treatment strategies. RWE 
studies can have very large sample sizes, can provide 
information on treatments in patient groups that are 
usually excluded from RCTs, are generally less expensive 
and quicker than RCTs, and can assess a broad range of 
outcomes. Limitations of RWE studies can include low 
internal validity, lack of quality control surrounding data 
collection and susceptibility to multiple sources of bias 
for comparing outcomes. RWE studies can complement 
the findings from RCTs by providing valuable information 
on treatment practices and patient characteristics among 
unselected patients. This information is necessary to guide 
treatment decisions and for reimbursement and payment 
decisions. RWE studies have been extensively applied in 
the postmarketing approval assessment of non-vitamin K 
antagonist oral anticoagulants since 2010. However, the 
benefits, costs, limitations and methodological challenges 
associated with the different types of RWE must be 
considered carefully when interpreting the findings.
IntroduCtIon
Randomised controlled trials (RCTs) are the 
gold standard for demonstrating the efficacy 
of a particular therapy or intervention.1–3 
However, RCTs are, by design, limited to a 
subset of patients who are not fully repre-
sentative of the unselected real-world popula-
tion.1 2 Patients enrolled in RCTs tend to show 
higher treatment adherence than those in 
clinical practice, they are positively disposed 
to some aspect of the treatment (as shown by 
their agreement to participate in the study) 
and they have fewer comorbidities in order 
to limit the impact of competing risks.4 RCTs 
tend to exclude patients who are very young, 
very old or who have major comorbidities, 
thereby limiting the relevance of their find-
ings to wider clinical practice.5 In addition, 
large-scale RCTs are expensive to conduct 
(~$50 million for a pivotal study) and have 
a long lead time from inception to comple-
tion.4 
Real-world evidence (RWE) is an umbrella 
term that has been broadly defined as infor-
mation derived from the analysis of data on 
health interventions used for healthcare deci-
sion-making, which has not been collected as 
part of an RCT but is typically from clinical 
practice.2 3 6 RWE is considered to better 
represent routine practice compared with 
the idealised conditions of an RCT.2 3 6 Data 
from RWE studies can complement findings 
from RCTs and, if appropriately designed, 
can provide valuable information about prac-
tice patterns and patient characteristics in a 
real-world setting.2 RWE studies are subject to 
some patient selection because such studies 
are unable to capture all types of patients, for 
example, patients who have not presented to 
a physician or are yet to be diagnosed. RWE 
studies provide a valuable reflection of the 
range and distribution of patients observed 
in the clinical practice setting.2
This review article discusses the utility, 
strengths and limitations of RWE studies, 
as well as potential developments to further 
bridge the gap between RCTs and daily clin-
ical practice.
StrengthS and lImItatIonS of rWe StudIeS
RWE studies include a wide range of research 
methodologies and data sources, although 
they can be broadly categorised into non-in-
terventional studies, patient registries, claims 
database studies, patient surveys and elec-
tronic health record studies (table 1).2 5
They can also be categorised into prospec-
tive studies, which generally require primary 
data collection, or retrospective studies, 
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Table 1 Summary of the main types of RWE studies and their key characteristics2 5 10 11
Study type Design Conventional uses Key characteristics compared with RCTs
Non-interventional studies, 
including pragmatic trials
Prospective or retrospective, non-
interventional, observational
Includes cohort, cross-sectional 
and case–control studies
 ► Incidence, cause and prognosis 
(cohort)
 ► Prevalence and cause (cross-sectional)
 ► Predictors of outcome (case–control)
Advantages
 ► Cohort: important in assessing risk factors where 
an RCT may be unethical; chronology enables 
clear distinction between cause and effect; several 
outcomes may be studied simultaneously; quick and 
inexpensive.
 ► Cross-sectional: most efficient way to determine 
prevalence; quick and inexpensive; several 
outcomes may be studied simultaneously.
 ► Case–control: case-efficient; useful for studying 
rare conditions or those with a long latency between 
exposure and disease; can assess many variables.
Disadvantages
 ► Cohort: recall bias; inefficient for studying rare 
outcomes; loss to follow-up can significantly 
affect outcomes; data quality issues (potential for 
missing data) especially in retrospective studies; 
prospective studies with comparator arm may be 
subject to treatment-allocation bias because of lack 
of randomisation.
 ► Cross-sectional: difficult to clearly distinguish 
cause and effect; may be inefficient for very rare 
conditions; uses questionnaires.
 ► Case–control: susceptible to sampling bias, 
observational bias and recall bias; can only assess 
one outcome; risk of cross-contamination between 
studies.
Patient registries Prospective, observational cohort 
study
 ► Natural history of disease
 ► Real-world safety and effectiveness
 ► Prognosis and quality of life
 ► Quality of care
 ► Cost-effectiveness
Advantages
 ► Larger and more diverse population; longer follow-
up.
 ► Few or no required study centre visits, evaluations 
or procedures.
 ► Can identify the most cost-effective treatment 
approaches.
 ► Data are captured in real time.
Disadvantages
 ► Lack of randomisation means that patient groups 
may not be comparable; problems of dose 
adjustment.
 ► Data quality issues: potential for missing data; 
variance in the quality of data between registries, 
due to differences in audit and control measures.
 ► Limits to the amount of data that can be collected.
 ► Data may not be collected at fixed time intervals.
Administrative and claims 
database studies
Retrospective  ► Longitudinal and cross-sectional 
analyses of clinical and economic 
outcomes
 ► Natural history of disease
 ► Real-world safety and effectiveness
Advantages
 ► Very large in size; can be used to identify rare 
events more easily, assess economic impact 
of various interventions and gain insight into 
associations between interventions and outcomes.
 ► Quick and inexpensive.
 ► Useful in assessing healthcare resource utilisation 
and costs.
Disadvantages
 ► Lack of randomisation means patient groups may 
not be comparable.
 ► Data quality issues: missing data; coding errors; 
inconsistency of coding/outcome definitions 
between centres or countries.
 ► Limited information on health outcomes, health 
status and symptoms.
 ► Limited validation.
Disadvantages specific to claims database studies
 ► Absence of a population denominator.
 ► Patients can switch between insurance companies, 
which may limit duration of follow-up.
Continued
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which use secondary data to look back in time (ie, data 
initially collected for other purposes; figure 1).
Potential strengths of rWe studies
RWE studies aim to include patient populations that are 
far more representative of the unselected population 
than those of RCTs; they can have very large sample sizes 
and can provide information on treatment practices in 
specific populations that are usually excluded from RCTs 
(eg, elderly patients or those with renal impairment).5 
This enhances the external validity (ie, the generalisa-
bility) of their findings compared with RCTs, which have 
restricted inclusion characteristics.5 RWE studies are less 
expensive and faster to complete than RCTs, and they can 
assess treatment patterns across a much broader range 
of outcomes. As well as broadly assessing safety and clin-
ical treatment patterns, and effectiveness outcomes (in 
studies comparing new treatments with standard of care), 
RWE studies can include assessments of treatment adher-
ence, treatment persistence, epidemiology, burden of 
Study type Design Conventional uses Key characteristics compared with RCTs
Electronic health record studies Retrospective, observational, 
medical record study
 ► Clinical treatments, procedures and 
outcomes
Advantages
 ► Capture real-time clinical treatment, outcomes, 
techniques and procedures.
 ► Can study rare conditions or those with a long 
latency between exposure and disease.
 ► Quick and inexpensive.
Disadvantages
 ► Requires sophisticated data management and 
statistical tools.
 ► Data quality issues: missing data, recording/coding 
errors, interpretive or recall biases.
 ► Lack of randomisation means patient groups may 
not be comparable.
 ► Typically limited to a small number of study centres.
Patient surveys Online, interview or paper-based 
questionnaire
 ► Health status and well-being
 ► Patient preferences
 ► Healthcare resource utilisation
 ► Treatment patterns and expenditure
Advantages
 ► Methodologically rigorous in their collection of data.
 ► Can provide information on the generalisability of 
treatments, their impact, healthcare utilisation and 
costs.
Disadvantages
 ► Lack of relevant data on specific treatments/
products.
 ► Recall and subjectivity bias.
RCT, randomised controlled trial; RWE, real-world evidence.
Table 1 Continued 
Figure 1 Illustration to highlight the design and analysis time frame (relative to the study start or index date) of different types 
of real-world evidence studies. Arrows depict prospective or retrospective studies of various durations.
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disease, prescribing patterns, health resource utilisation 
and cost-effectiveness.5 They also have the capacity to 
assess overall outcomes in various patient and risk groups 
and, because they may be conducted in an unselected 
population over a long time frame, can provide insights 
into toxicity, long-term safety and rare adverse events.2 5
Potential limitations of rWe studies
Traditionally, methodological and study design issues, 
such as the risk of confounding and bias, have prevented 
non-randomised observational studies from being 
considered useful for the assessment of new medical 
treatments or interventions. Even a well-designed, 
robust, non-randomised study would be considered 
to be lower grade evidence compared with a poorly 
designed RCT.7 Currently, the value of RWE is much 
better understood, with RWE studies now forming a key 
part of the postauthorisation evaluation of an approved 
drug, at the request of regulatory authorities.7 8 However, 
possible limitations should still be considered.7 The key 
limitation of RWE studies is the lack of randomisation. 
Although this contributes to the high external validity 
of the data, it reduces the internal validity of the data 
(ie, the extent to which any differences between the 
intervention and control groups can be attributed to 
the intervention itself, as opposed to other factors).5 9 
In addition, without a controlled clinical study environ-
ment, there may be little or no control over the quality 
of the data collection in RWE studies, although measures 
can be taken to optimise this.5 For example, prospective 
patient registries may have quality-control measures and 
auditing procedures to improve data integrity, including 
the use of real-time electronic data capture, personnel 
training, independent adjudication of outcomes and the 
use of data or coding dictionaries to ensure standardised 
outcome definitions.2 10 Retrospective comparisons are 
prone to multiple biases, including sampling bias, recall 
bias, confounding by indication and changes in practice 
and/or disease biology.5 11 Statistical approaches have 
been developed that aim to adjust for multiple types of 
bias (eg, propensity score adjustment, covariate adjust-
ment and others).2 However, serious confounding may 
remain due to the impact of unmeasured confounders 
and unmeasured risks on treatment decisions. Therefore, 
retrospective study data do not meet the reliability and 
accuracy afforded by the methodological rigour of RCTs.2 
The methods employed in developing treatment guide-
lines do not rank observational data as a reliable basis for 
comparing treatments or strategies.12 13
applications of rWe studies
Given their ability to evaluate clinical practice patterns 
and monitor long-term and infrequent safety events, RWE 
studies have been evaluated in postmarketing approval 
assessments of the non-vitamin K antagonist oral antico-
agulants (NOACs). Four NOACs (apixaban, dabigatran, 
edoxaban and rivaroxaban) are currently available for 
the prevention of stroke in patients with atrial fibrillation 
(AF) and the treatment of venous thromboembolism 
(VTE), but it is recommended that they are used with 
caution in patients with conditions where there is an 
increased risk of bleeding.14–17 Therefore, it is essential 
that factors such as dose selection and treatment adher-
ence are monitored outside of a controlled clinical envi-
ronment to see if they differ from pivotal RCTs18–21 and 
to determine their impact on clinical outcomes such as 
major bleeding, stroke or recurrent VTE. For this reason, 
many RWE studies have been, and are being, conducted 
to evaluate NOAC treatments; these will be used as exam-
ples to illustrate the value and limitations of the informa-
tion provided by the different RWE study types.
non-InterventIonal StudIeS
Non-interventional studies are defined as those where 
treatment is prescribed in accordance with the terms of 
the marketing authorisation, and where the assignment 
of the patient to a particular therapy is entirely at the 
physician’s discretion, rather than decided in advance by 
the study protocol.22 23 As such, treatment selection and 
management is separate from the decision to include the 
patient in the study, with no diagnostic or monitoring 
procedures performed above those deemed necessary by 
the attending physician for the conduct of the study.22 23 
In some instances, prospective, multicentre, non-inter-
ventional studies conducted in routine clinical practice 
may be referred to as pragmatic clinical trials.24 25
With the exception of registries (detailed in the next 
section), non-interventional studies generally fall into 
three categories: cohort, cross-sectional and case–control 
studies.11
Cohort studies
Cohort studies can be either prospective or retrospective, 
and typically assess the incidence, cause and prognosis 
of certain conditions/outcomes.11 In prospective cohort 
studies, patients are monitored until a relevant outcome 
occurs (eg, a major bleeding event, stroke or recurrent 
VTE for studies of NOACs),26 27 with data routinely 
collected on potential risk factors for the outcome.11 In 
retrospective cohort studies, the methodology is the same 
but the data have already been collected for a separate 
purpose and a post-hoc analysis is carried out.11
Advantages of cohort studies include the ability to assess 
a broad range of risk factors,28 including those where an 
RCT may be unethical (such as the impact of smoking or 
exposure to toxins), and the fact that several outcomes 
can be monitored simultaneously.11 The chronology of 
the study also enables a clear distinction between cause 
and effect (unlike cross-sectional studies), although this 
also means that loss to follow-up can significantly affect 
the outcomes, and studying rare outcomes can be ineffi-
cient.11 29 Retrospective cohort studies can be conducted 
quickly and inexpensively compared with RCTs because 
the data have already been collected. However, retro-
spective cohort studies can suffer from limited or missing 
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data, less rigour in data collection (no prestudy analysis 
plan or protocol) and recall bias, all of which are distinct 
disadvantages.11
The first international, prospective, multicentre, 
non-interventional study of a NOAC for stroke prevention 
in patients with AF was the single-arm XANTUS (Xarelto 
for Prevention of Stroke in Patients with Atrial Fibrilla-
tion) study of rivaroxaban. This was then followed by 
the XALIA (XArelto for Long-term and Initial Antico-
agulation in venous thromboembolism) study of rivar-
oxaban versus standard anticoagulation in patients with 
VTE.26 27 These studies, both examples of pragmatic 
trials, supported the results of RCTs, showing low inci-
dences of major bleeding (in both studies) and low rates 
of stroke (XANTUS) and recurrent VTE (XALIA) in 
patients receiving rivaroxaban in a real-world setting.26 27 
The problem with selection bias (eg, the idea that agree-
ment to participate in the survey might select a group 
that responds in a specific way) was noted in both studies, 
and efforts to minimise this using a single cohort design 
(XANTUS) or propensity score matching (XALIA) were 
employed.28 In both XANTUS and XALIA, outcomes 
were centrally adjudicated by investigators blinded to 
treatment in an attempt to reduce reporting bias.26 27 
However, missing data and the effects of unmeasured 
confounding factors could not be addressed.26 27
Cross-sectional studies
Cross-sectional studies involve the assessment of a single 
group of patients at a single point in time, at which treat-
ment and outcomes are determined simultaneously.11 29 
They are typically used to assess prevalence and infer the 
cause of conditions/outcomes.11 29 Cross-sectional studies 
can be conducted relatively quickly and inexpensively 
compared with RCTs, and can assess multiple outcomes 
simultaneously. They are, therefore, the most efficient way 
to determine the prevalence of a condition.11 29 However, 
because the data are collected at a single time point, it is 
difficult to clearly distinguish cause and effect—patients 
who develop an outcome but die before the end of the 
study are not captured, and they are susceptible to selec-
tion bias. This method is also inefficient for studying rare 
conditions because, even in large sample sizes, there may 
be few or no patients with the disease.11 29–31 Additionally, 
cross-sectional studies are often completed using ques-
tionnaires, which have inherent problems, including low 
response rates and susceptibility to various sources of bias 
(see later section on patient surveys).2 11 32
In the case of the NOACs, cross-sectional studies have 
provided insights into the prevalence of underdosing, 
how to achieve more appropriate dose selection,30 how 
closely the pivotal RCTs resemble a real-world popula-
tion33 and how successfully NOACs have been adopted 
into prescribing practices over time.31
Case–control studies
Unlike cohort and cross-sectional studies, case–control 
studies are usually conducted retrospectively.11 Patients 
who have experienced the outcome of interest are 
matched with a control group who have not experi-
enced this outcome, and exposure to treatment or other 
factors are assessed from medical history to determine 
causality.11 29 Because the patient population is selected 
based on the outcome, case–control studies are espe-
cially useful in studying rare conditions or those with a 
long latency between exposure and disease, although 
the study is limited to investigating a single outcome.11 
They can also consider many variables simultaneously, 
providing a case-efficient way of identifying potential 
predictors of specific outcomes.11 However, case–control 
studies are often conducted by an interview, which 
makes them susceptible to sampling bias (eg, recruit-
ment of cases or controls from single sources), obser-
vational bias (eg, interviewers assessing cases differently 
from controls) and recall bias (eg, cases being more 
likely to recall past exposure than controls because they 
have considered the cause of the condition), as well as 
unmeasured confounders.11 29 34 Because of these limita-
tions, the results of case–control studies are most appro-
priately used for hypothesis generation,11 34 35 and have 
primarily been used to assess whether NOAC treatment 
is a risk factor for rare outcomes or safety outcomes in 
specific patient populations.34–36
PatIent regIStrIeS
Patient registries are non-interventional, observational 
cohort studies.2 They are typically prospective studies 
that involve standardised, ongoing data collection in a 
real-world setting to fulfil a specific predefined purpose, 
where management of treatment and care is determined 
by the patient and caregiver rather than the registry 
protocol.10 Ideally, the collection of registry data is 
uniform for all patients, including the type, method and 
frequency of collection. Information is then collated in a 
central registry database for analysis.
Advantages of registries over RCTs include the capacity 
to enrol a much larger and more diverse patient popu-
lation with the potential for a longer follow-up period. 
This provides data that are more reflective of a real-
world population and enables the study of longer term 
outcomes, including the identification of more infre-
quent safety outcomes.2 Registry studies also involve 
few or no required visits, evaluations or procedures at 
specialist centres because the data are collected by the 
attending physician as part of daily practice. Not only does 
this make registries potentially less expensive than RCTs, 
but it also means that treatment patterns reflect the daily 
clinical decision-making that is most relevant to health-
care providers and payers, and can help identify the most 
cost-effective treatment approaches.2 In addition, regis-
tries are sometimes linked with other databases, which 
can enable the assessment of separate outcomes such as 
healthcare utilisation and mortality.10
These factors make registries particularly useful for 
assessing (1) the natural history of a disease; (2) real-world 
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safety and effectiveness; (3) prognosis and quality of life; 
(4) quality of care; and (5) cost-effectiveness of treatment 
strategies.10
As with all observational studies, a disadvantage 
inherent to patient registries is that the lack of rando-
misation means there is no guarantee that the patient 
groups are similar (because of factors such as dose adjust-
ments), which can reduce the internal validity of the 
findings. Importantly, retrospective registries are also 
subject to survivor bias because they exclude deaths 
prior to the registry start date, and time from diagnosis to 
enrolment is longer for the patients included compared 
with prospective studies, meaning these registries will 
not encompass high-risk periods after disease onset.2 
Because the data in registries are collected from a wide 
variety of different centres, sometimes across different 
countries, there can also be considerable variation in the 
auditing and control measures employed and the quality 
of the data collected.2 In addition, variations between 
countries and centres regarding the requirement and 
processes for obtaining informed patient consent can 
also lead to authorisation or selection bias.37 38 Further-
more, there are limits to the amount of data that can 
be obtained in a routine clinical practice visit, and the 
visits may not be scheduled at regularly timed intervals, 
hindering comparisons between patient groups. Despite 
this, the advancement of modern technologies such as 
mobile phone apps and cloud computing may make it 
far easier to collect data in a more uniform fashion and 
in real time, thus enabling more rigorous monitoring of 
data collection.2
Data on NOAC use in patients with AF or VTE are 
provided by several large registries, including the 
regional Dresden NOAC Registry, the national ORBIT 
AF I/II (Outcomes Registry for Better Informed Treat-
ment of Atrial Fibrillation) registries and the multina-
tional GARFIELD-AF (Global Anticoagulant Registry in 
the FIELD-Atrial Fibrillation), GARFIELD-VTE (Global 
Anticoagulant Registry in the FIELD-Venous Thrombo-
embolism) and GLORIA-AF (Global Registry on Long-
Term Oral Antithrombotic Treatment in Patients with 
Atrial Fibrillation) registries (table 2).
Table 2 Overview of key prospective registries for stroke prevention in patients with AF and treatment of VTE
Registry Design Objective
GARFIELD-AF69 International, multicentre registry; target n=55 
000 patients at >1000 centres in 50 countries.
To assess treatment management and outcomes in 
patients with newly diagnosed AF and one or more 
additional risk factors for stroke.
ORBIT AF I70 Multicentre outpatient registry in the USA of over 10 000 
patients.
To assess current practice patterns, adherence and 
resource use in patients with AF and the adoption and 
impact of NOACs.
ORBIT AF II43
February 2013–ongoing
Multicentre outpatient registry targeting 15 000 patients in 
300 US practices with newly diagnosed AF and/or with AF 
who recently transitioned to NOAC treatment.
To assess the clinical status, outcomes (major adverse 
cardiovascular events, bleeding) and management of 
anticoagulation, as well as the use of NOACs.
GLORIA-AF71 International, multicentre registry; target n=56 
000 patients at ≤2200 sites in <50 countries.
To characterise patients with newly diagnosed AF at risk 
of stroke in various regions of the world; to describe 
antithrombotic treatment patterns; to collect data on the 
effectiveness and safety of NOACs compared with VKAs.
PREFER in AF registry72 Multicentre registry in 7 European countries; 
n=7243 patients enrolled from 461 centres.
To gain insight into the characteristics and management of 
patients with AF.
Dresden NOAC Registry39 Registry of patients treated with NOACs in private 
practices and hospitals in the Saxony region of Germany.
To collect data on the effectiveness, safety and 
management of NOAC therapy in daily care.
RIETE
2001–ongoing73
International, multicentre registry of patients with VTE. To evaluate outcomes in patients with VTE.
GARFIELD-VTE
March 2014–ongoing74
International multicentre registry; target n=10 000 patients 
from ~500 sites in 28 countries.
To assess the duration of anticoagulation management 
and clinical and economic outcomes in patients with acute 
VTE in the real-world setting.
PREFER in VTE registry75 Multicentre registry in 7 European countries; 
n=3545 patients enrolled from 381 centres.
To assess the management of patients with VTE, use of 
healthcare resources and costs of treatment in patients 
diagnosed with VTE in hospitalised or specialist centres 
across Europe.
SWIVTER44 Swiss multicentre registry. To evaluate outcomes in patients with VTE.
AF, atrial fibrillation; GARFIELD-AF, Global Anticoagulant Registry in the FIELD-Atrial Fibrillation; GARFIELD-VTE, Global 
Anticoagulant Registry in the FIELD-Venous Thromboembolism; GLORIA-AF, Global Registry on Long-Term Oral Antithrombotic 
Treatment in Patients with Atrial Fibrillation; NOAC, non-vitamin K antagonist oral anticoagulant; ORBIT AF, Outcomes Registry for 
Better Informed Treatment of Atrial Fibrillation; PREFER in AF, PREvention oF thromboembolic events — European Registry in Atrial 
Fibrillation; PREFER in VTE, PREvention oF thromboembolic events — European Registry in Venous Thromboembolism; RIETE, 
Registro Informatizado de Pacientes con Enfermedad TromboEmbólica; SWIVTER, SWIss Venous ThromboEmbolism Registry; VKA, 
vitamin K antagonist; VTE, venous thromboembolism.
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Results from these registries have provided insights 
into the management of NOAC treatment in clinical 
practice, including switching from warfarin to NOACs, 
the identification of high-risk patient populations and 
the high levels of inappropriate NOAC dosing that occur 
in clinical practice.39–42 However, reported limitations 
to the interpretation of these findings include missing 
or incomplete data, selection bias and residual/unmea-
sured bias due to a lack of randomisation.39–43
Long-term clinical outcomes in the majority of the 
above registries are currently being acquired because the 
studies are still ongoing, but initial results support the 
use of NOACs in patients with AF and patients treated 
for VTE. For example, in SWIVTER (SWIss Venous 
ThromboEmbolism Registry), a study of patients treated 
for VTE, the risk of recurrent VTE was similar in the 
rivaroxaban treatment arm compared with the conven-
tional anticoagulation arm (1.2% vs 2.1%, P=0.29) for 
the propensity score-adjusted population; the risk of 
major bleeding was also similar (0.5% vs 0.5%, respec-
tively, P=1.00).44 Patients with AF receiving rivaroxaban 
for stroke prevention in the Dresden NOAC Registry 
were also analysed (n=1204). The combined endpoint 
including stroke, transient ischaemic attack and systemic 
embolism occurred at a rate of 2.03 per 100 patient-years 
in the intention-to-treat analysis (95% CI 1.5 to 2.7). Major 
bleeding in the on-treatment group occurred at a rate of 
3.0 per 100 patient-years. Event outcomes in the on-treat-
ment group were higher in patients receiving rivarox-
aban 15 mg once daily compared with rivaroxaban 20 mg 
once daily (stroke/transient ischaemic attack/systemic 
embolism 2.7 vs 1.25 per 100 patient-years and major 
bleeding 4.5 vs 2.4 per 100 patient-years, respectively).45 
Similar results were observed in analyses performed in 
patients with AF receiving apixaban and dabigatran for 
stroke prevention in the Dresden NOAC Registry.46 47
admInIStratIve and healthCare ClaImS databaSe 
StudIeS
These studies involve retrospective (or sometimes real-
time) analysis of data from administrative and healthcare 
claims databases containing treatment information and 
clinical information, such as diagnosis codes and hospital 
admissions/discharge dates.2 48 As such, these databases 
are particularly suited to longitudinal and cross-sectional 
analyses of healthcare utilisation and costs at the patient, 
group or population level,2 although insights can also 
be gained into associations between interventions and 
outcomes using the (although sometimes limited) clin-
ical information.
The key advantages of administrative and healthcare 
claims database studies are that they can be performed 
relatively quickly and inexpensively compared with RCTs, 
involve a very large established patient cohort and can 
have a long follow-up period. This enables the identifi-
cation of rare events, the determination of longer term 
outcomes and insight into the economic impact of 
interventions.2 In some instances, database information 
can also be linked with clinical data, such as patient-re-
ported outcomes, laboratory assessments, medical records 
and physician surveys. This practice is most common in 
countries such as Denmark and Sweden, where every 
member of the populace has a unique personal identi-
fication number, enabling lifelong follow-up and linkage 
between databases at the individual level. The informa-
tion contained within these Scandinavian administrative 
databases has been used to assess the comparative effec-
tiveness and safety of the NOACs for stroke prevention in 
patients with AF; regression or propensity-based adjust-
ment was used to try to reduce bias from confounding 
variables inherent in a non-interventional observa-
tional analysis.49–51 Similar approaches have been used 
in numerous studies using data from healthcare claims 
databases, particularly to assess the risk of bleeding events 
in NOAC-treated patients and adherence/persistence to 
treatment (table 3).52–55
Administrative and claims databases, however, lack key 
information about the choice of therapy. This choice 
can be influenced by clinical risk factors and physician 
and patient preferences which are not recorded in such 
databases. In addition, databases lack clarity in terms of 
insights into dosing. All these factors make inferences 
from administrative and claims databases, particularly 
direct drug comparisons, unreliable in relation to the 
clinical effectiveness of specific treatments. Data quality 
is also one of the major disadvantages of these data-
base studies. Clinical data may not only be limited or 
missing (eg, health outcomes, health status, symptoms 
and patient characteristics, such as creatinine clearance 
levels, international normalised ratio values or time in 
therapeutic range),2 52 55 56 but the accuracy of reporting 
is variable (both between different countries and between 
centres within the same country) and coding errors are 
common.49 52 55 With respect to NOAC studies, there are 
many different codes and categories for bleeding events, 
further increasing the chances of coding errors (eg, gastro-
intestinal bleeding is often listed as ‘bleeding of unknown 
source’), and diagnosis codes (eg, International Classifica-
tion of Diseases, Ninth or Tenth Revision) may not always 
differentiate between indications.52 Therefore, caution 
should always be exercised when interpreting treatment 
effectiveness and safety based on claims database analyses.
Even if the integrity of the data can be confirmed, 
there are additional issues inherent to claims database 
analyses, including limited validation, lack of a population 
denominator and lack of distinction between costs and 
charges2; follow-up duration may be limited by patients 
switching between insurance plans. However, selection 
bias is perhaps the most common and challenging meth-
odological issue affecting both administrative and claims 
database analyses because treatment selection, clinical 
outcomes and economic outcomes could be influenced 
by factors that are not recorded in the database (eg, 
baseline health status, symptomatology and comorbidi-
ties).2 49 54 55 57
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eleCtronIC health reCord StudIeS
Electronic health record studies are retrospective (or 
sometimes real-time), observational analyses of data 
sourced directly from medical records or charts.2 58 They 
are typically used to assess clinical treatments, procedures 
and outcomes.
Like claims database studies, electronic health 
record studies can be performed relatively quickly and 
Table 3 Examples of healthcare administrative and claims databases and associated NOAC studies
Claims database Design Study examples Results
CNODES multicentre database USA and Canada; healthcare data from 
five Canadian provinces and the USA.
Jun et al76
n=59 525
No increase in risk of major bleeding or all-cause mortality was 
associated with NOACs compared with warfarin in patients with 
venous thromboembolic events, within the first 90 days of treatment 
(major bleeding, HR=0.92, 95% CI 0.82 to 1.03; death, HR=0.99, 
95% CI 0.84 to 1.16).76
Medicare programme USA; retrospective healthcare claims 
database.
Graham et al54
n=134 414
Graham et al53
n=118 891
Dabigatran was associated with a reduced risk of ischaemic stroke, 
ICH and death but was also associated with an increased risk 
of major GI bleeding, compared with warfarin in elderly patients 
with NVAF.54 Treatment with rivaroxaban was associated with a 
non-significant reduction in thromboembolic stroke compared 
with dabigatran. However, a significant increase in ICH and major 
bleeding rates compared with dabigatran was also noted.53
US Truven Health MarketScan USA; retrospective commercial claims 
and Medicare supplemental database.
Coleman et al55
n=22 822
Rivaroxaban was associated with a significantly lower combined rate 
of both stroke and ICH compared with warfarin (HR=0.61, 95% CI 
0.45 to 0.82). This rate was lower but non-significant for apixaban 
compared with warfarin.55
National database Denmark; nationwide registry study 
linking data from across several Danish 
administrative registries.
Sindet-Pedersen et al77
n=12 318
Rivaroxaban was associated with a similar major bleeding risk and 
risk of recurrent VTE compared with VKA treatment (major bleeding 
2.28% vs 2.10%; recurrent VTE 3.03% vs 3.13%, respectively).77
1. Danish National Prescription 
Registry78
1994
1. National database including purchase 
date, ATC code, package size and dose 
units.
Sørensen et al56 In patients receiving dabigatran, an increased risk of 
thromboembolism (dabigatran 110 mg and 150 mg) and bleeding 
(dabigatran 110 mg only) was observed if patients had prior use of 
VKAs, compared with the VKA treatment arm.56
2. Danish National Patient Register48
1977
2. National database including hospital 
admission and discharge dates, 
discharge diagnoses (ICD).
Larsen et al50 No significant difference was observed between NOACs and warfarin 
for rates of ischaemic stroke. For apixaban and dabigatran, the risk 
of death, any bleeding and major bleeding was significantly lower 
compared with warfarin. Rivaroxaban was associated with similar 
bleeding and death rates compared with warfarin.50
3. Danish Civil Registration System79 
1968 
3. National database including 
age, gender, date of birth, vital and 
emigration status.
Nielsen et al49 When NOACs were used at a reduced dose, no significant difference 
was observed for the risk of ischaemic stroke/systemic embolism 
between NOACs and warfarin. Bleeding rates were significantly 
lower for dabigatran compared with warfarin and similar bleeding 
rates observed for rivaroxaban and apixaban compared with 
warfarin.49
Vårdanalysdatabasen Regional database of Stockholm area of 
Sweden, which includes data relating 
to hospitalisations/other healthcare 
consultations (including primary care 
and outpatient visits), diagnoses and 
prescription claims (derived from 
National Prescribed Drug Register).
Forslund et al51
n=22 198
Forslund et al80
n=13 390
Similar risks of TIA/ischaemic or unspecified stroke/death and 
severe bleeding were demonstrated for patients with AF treated with 
NOAC and warfarin (HR=0.94, 95% CI 0.85 to 1.05 and HR=1.02, 
95% CI 0.88 to 1.19). Lower risks were associated with NOACs 
for intracranial bleeding (HR=0.72, 95% CI 0.53 to 0.97) and 
haemorrhagic stroke (HR=0.56, 95% CI 0.34 to 0.93) compared with 
warfarin, but a higher risk was observed with NOACs for GI bleeding 
(HR=1.28, 95% CI 1.04 to 1.59).51
For patients with NVAF receiving OACs, the 1-year crude persistence 
rates were 85.9% with apixaban, 74.4% with dabigatran, 77.4% for 
rivaroxaban and 85.0% for warfarin.80
Swedish Patient Register National database including hospital 
admission and outpatient visits including 
diagnoses and procedures (ICD).
Friberg and Oldgren81
n=68 056
Risks for all-cause stroke and systemic embolism were similar with 
NOACs and warfarin (HR=1.04, 95% CI 0.91 to 1.19). Significantly 
lower risks were observed with NOACs for major bleeding (HR=0.85, 
95% CI 0.76 to 0.96), ICH (HR=0.60, 95% CI 0.47 to 0.76) and 
all-cause mortality (HR=0.89, 95% CI 0.81 to 0.96) compared with 
warfarin. However, a higher risk was observed for GI bleeding in the 
NOAC group (HR=1.22, 95% CI 1.01 to 1.46).81
Swedish Prescribed Drug Register National database including details 
about every dispensed prescription.
Swedish Cause of Death Register National database including cause of 
death.
Swedish socioeconomic longitudinal 
integration database for health 
insurance and labour market studies 
(LISA) register
National database including 
demographic information (eg, 
educational level, occupation, income).
AF, atrial fibrillation; ATC, Anatomical Therapeutic Chemical Classification; CNODES, Canadian Network for Observational Drug Effect Studies; GI, 
gastrointestinal; ICD, International Classification of Diseases; ICH, intracranial haemorrhage; NOAC, non-vitamin K antagonist oral anticoagulant; NVAF, non-
valvular atrial fibrillation; OAC, oral anticoagulant; TIA, transient ischaemic attack; VKA, vitamin K antagonist; VTE, venous thromboembolism.
 o
n
 8 M
ay 2018 by guest. Protected by copyright.
http://openheart.bmj.com/
O
pen Heart: first published as 10.1136/openhrt-2018-000788 on 21 April 2018. Downloaded from
 
9Camm AJ, Fox KAA. Open Heart 2018;5:e000788. doi:10.1136/openhrt-2018-000788
Arrhythmias and sudden death
inexpensively compared with RCTs, can involve a rela-
tively large patient cohort and can have a longer follow-up. 
The study of rare conditions or those with a long latency 
between exposure and disease is also possible,58 as is the 
study of the real-world use of specific techniques, treat-
ments and procedures.2 Although health record studies 
are usually limited to a small number of study centres, 
central databases such as the UK Clinical Practice 
Research Datalink are becoming more widely available 
with the proliferation of mobile technologies.2 59 These 
databases enable longitudinal, patient-level data collec-
tion from multiple sources and may contribute to more 
consistent recording and coding of information.
Although real-time clinical treatment and outcomes 
data are captured in electronic health record studies, 
there are similar issues to those of claims database studies 
regarding data integrity. Findings are heavily reliant on 
the accuracy of recorded information or the recall of indi-
viduals. Therefore, there is the potential for recording/
coding and interpretive errors or bias.2 58 60 Transforming 
the data for research purposes requires sophisticated 
statistical tools, and making robust inferences on clin-
ical effectiveness and safety based on chart review data 
remains a challenge.2
Nevertheless, recent electronic health record studies of 
NOACs have supported the findings of the pivotal RCTs 
and provided insights into the safety of NOAC use and 
treatment persistence.60–63
PatIent SurveyS
Patient and health surveys are designed to collect health 
status, well-being, healthcare resource utilisation, treat-
ment patterns, education and treatment preference 
information from patients, healthcare providers or the 
general population.2 32 They can be conducted in a 
variety of ways, but typically involve either online, inter-
view or paper-based questionnaires.32 64–66 Patient surveys 
usually include a rigorous methodology for the collec-
tion of data and can provide unique information on the 
generalisability of treatments, their impacts at a patient 
level and adherence in the real world.2 With regard to 
NOACs, patient surveys have proved particularly useful 
in identifying factors that influence patient–physician 
decision-making, the need for improved patient educa-
tion and adherence (including physician adherence to 
appropriate monitoring), and both patient and physician 
treatment preferences.32 64–66
Patient surveys, however, lack relevant data on specific 
treatments or products.2 Therefore, they cannot be used 
to evaluate the effectiveness or safety of treatments, other 
than by inference from patient or physician percep-
tions, and are susceptible to various forms of bias. These 
include recall bias, selection bias and subjectivity bias (eg, 
positive response bias, where a patient may respond in a 
way they believe to be appropriate rather than reporting 
their actual behaviour).2 32 Although efforts can be 
made to minimise these issues, such as validation of the 
questionnaire prior to the survey, question/response 
randomisation or validation of responses within the ques-
tionnaire itself,32 64 these biases should always be consid-
ered when interpreting the results of any survey.
Study overvIeW and ComParISon WIth rCtS
The completed RWE studies listed in this review show 
consistent results in terms of effectiveness and safety with 
other studies investigating NOACs, including the find-
ings from phase III RCTs (table 4). However, it is impor-
tant to note that no comparisons between RWE studies 
and RCTs or other types of studies can be made.26 27
PraCtICal and ProCedural ConSIderatIonS
Overall, there are several key aspects to consider when 
evaluating and comparing data from RWE studies. 
Perhaps most important is whether the study design 
is appropriate for the study outcomes. As detailed in 
previous sections, different study designs lend themselves 
to different outcomes: RCTs are the gold standard for 
the evaluation of efficacy and for comparing treatments; 
claims database studies may be the most appropriate for 
healthcare utilisation; cross-sectional studies can be used 
to assess prevalence; case–control and electronic health 
record studies are useful for rare conditions; and patient 
registries can investigate the natural history of a condi-
tion. Real-world clinical safety and effectiveness can be 
assessed using various RWE study types (and there is 
an argument that these should be obtained to provide 
the most balanced overview for an intervention), but it 
appears that prospective, non-interventional studies and 
patient registries provide the most robust data on these 
outcomes.
It is also essential that the study population reflects the 
target population. For example, the interpretation of 
health claims database findings should consider the spec-
ificity of diagnosis codes and the breadth of insurance 
coverage.
It is vital to consider the inherent sources of bias in 
the study designs when drawing the appropriate conclu-
sions from RWE studies and comparing the findings 
with previous studies. These are far more numerous and 
varied than those of RCTs, from the positive response 
bias in patient surveys to the selection bias and poten-
tial for data-mining in administrative and claims database 
studies. There are sophisticated statistical approaches 
that can adjust for bias, including logistic regression 
adjustment, inverse probability weighting, propensity 
(or other) matching, instrumental variable methods and 
panel data models.67 However, despite these approaches, 
RWE study data still do not meet the reliability and accu-
racy afforded by the methodological rigour of RCTs and 
do not provide a reliable way of comparing treatment 
strategies.2
Lastly, one of the most common issues with RWE 
studies is the quality and consistency of data collection. 
When comparing data between studies, the type of data 
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(eg, prospective, retrospective, adjudicated, non-inter-
ventional, database, survey), outcome definitions, choice 
of database codes, auditing and control measures, and 
methodologies to adjust for missing data, under-re-
porting, coding errors and others should be aligned to 
enable robust comparisons. Overall, inferences drawn 
from observational and retrospective RWE studies can be 
made, but this should be done with caution and inter-
pretations need to take account of the design, robustness 
and quality assurance in each study.
ConCluSIonS
RWE studies can complement the findings from RCTs, 
provide valuable information on treatment practices 
and patient characteristics in a real-world setting, and 
are essential to the evidence base required for sound 
coverage and payment decisions.2 However, it is crit-
ical that the benefits, costs, limitations and methodo-
logical challenges associated with the different forms 
of RWE are carefully considered when interpreting the 
findings,2 as highlighted by guidance from regulatory 
and industry bodies.6 67 68 Moreover, despite the use of 
sophisticated statistical approaches to adjust for bias, 
there will always be residual confounding in compar-
ative studies because of the absence of randomisation; 
therefore, results should be considered as hypothe-
sis-generating and should not be viewed as a substitute 
for RCTs.
The registration of retrospective studies, in the same 
fashion as prospective trials, may help standardise data 
collection, interpretation and reporting, improve the 
consistency of methodological rigour across RWE studies, 
and help to bridge the gap between RCTs and clinical 
practice.
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Table 4 RWE study overview for use of NOACs in routine clinical practice (excluding registries and claims databases)
Study Design Objective Key findings
XANTUS26 Prospective, observational, 
international study of patients 
treated with rivaroxaban for stroke 
prevention in patients with AF.
To investigate the safety and 
effectiveness of rivaroxaban in 
routine clinical use in the AF 
setting.
At the 1-year follow-up (n=6784), event rates of stroke and 
major bleeding in patients treated with rivaroxaban were low 
(event rates per 100 patient-years were 2.1 for treatment-
emergent major bleeding, 1.9 for death and 0.7 for stroke).
XALIA27 Prospective, non-interventional, 
international study of patients with 
DVT.
To assess the effectiveness and 
safety of rivaroxaban compared 
with standard anticoagulation 
therapy.
In the propensity score-adjusted population (n=4515), results 
confirmed that rivaroxaban was a well-tolerated and effective 
alternative to standard anticoagulation therapy. Rates of major 
bleeding and recurrent VTE were low in the rivaroxaban group 
compared with standard anticoagulation therapy (0.8% vs 
2.1% (P=0.44) and 1.4% vs 2.3% (P=0.72), respectively).
NOAC-TURK study30 Multicentre cross-sectional study 
in Turkey.
To evaluate the current patterns 
in NOAC treatment in Turkey, to 
include demographics and clinical 
outcomes.
A total of 2862 patients were included and the most frequent 
indication for NOACs was AF (83.3%). Bleeding events occurred 
in 7.6% of patients (1.1% major bleeding) and embolic events 
were observed in 1.3%. Rivaroxaban and dabigatran were 
preferred compared with apixaban, and 47.6% were receiving 
suboptimal doses of NOACs.
Tamayo et al34 Nested case–control post-
marketing safety surveillance study.
To assess major bleeding risk 
factors using data from an ongoing 
safety study of patients with AF 
treated with rivaroxaban.
The study included 542 cases and 2710 controls and the risk 
factors for major bleeding identified were generally consistent 
with those published previously. The strongest risk factors 
identified were increased age, anaemia, prior GI bleeding, heart 
failure and vascular disease (P<0.0001, all factors).
European Heart Rhythm 
Association survey65
Multinational self-assessment 
survey in patients with AF.
To assess patients’ attitudes, 
level of education and knowledge 
concerning OACs.
A total of 1147 responses were gathered from across Europe. 
OAC treatment was used by 77% of patients, with around 
one-third of these patients receiving NOACs. Compliance 
was identified as an issue in patients with AF, with 14.5% 
of patients temporarily discontinuing treatment and 26.5% 
missing at least one dose (self-reported). Further patient 
education is required to improve treatment adherence and 
knowledge of treatment monitoring.
Sauter et al66 Paper-based pilot survey of Swiss 
practitioners on their knowledge 
of NOACs.
To assess the knowledge of 
Swiss general internal medicine 
physicians around follow-up, 
guidelines, dosing adjustments, 
complications and indications.
Of the 53 physicians who completed the survey, NOACs were 
seen to be well-accepted as the first-choice treatment in newly 
diagnosed patients. Two-thirds of the respondents adhered to 
clinical follow-up guidance and bleeding complication rates 
were low (1.9 events±2.87 in the previous 2 years), with the 
majority managed without admission to hospital.
AF, atrial fibrillation; DVT, deep vein thrombosis; GI, gastrointestinal; NOAC, non-vitamin K antagonist oral anticoagulant; OAC, oral 
anticoagulant; RWE, real-world evidence; VTE, venous thromboembolism; XALIA, XArelto for Long-term and Initial Anticoagulation in venous 
thromboembolism; XANTUS, Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation.
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